Download PDF
psychoneuro 2005; 31(10): 499-503
DOI: 10.1055/s-2005-922238
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Trends in der Angsttherapie

Trends in the treatment of Anxiety DisordersDirk Wedekind1 , Borwin Bandelow1
  • 1Klinik für Psychiatrie und Psychotherapie der Georg-August-Universität Göttingen
Further Information

Publication History

Publication Date:
22 November 2005 (online)

   Permissions and Reprints

Zusammenfassung

Bei der Behandlung von Angststörungen wird heute eine Kombination von Pharmakotherapie und Kognitiver Verhaltenstherapie empfohlen. Neue Entwicklungen zielen auf schnellere, breitere Wirkung bei verbesserter Verträglichkeit, möglichst auch bei multimorbiden Patienten. Bei den Benzodiazepinen werden z.B. speichellösliche Darreichungsformen entwickelt. Neuentwicklungen bei den Antidepressiva sind z.B. das enatiomerenreine Escitalopram, retardiertes Paroxetin und der Serotonin- und Noradrenalin-Wiederaufnahmehemmer Duloxetin. Neue Behandlungsstrategien sind u.a. die Augmentation mit atypischen Antipsychotika. In der Pipeline stehen außerdem selektive Serotonin-Rezeptorliganden, neue GABA-A-Liganden, Antikonvulsiva, Neuropeptide, Neurosteroide und Modulatoren der neuroendokrinen Stressreaktion.

Summary

For the treatment of anxiety disorders, a combination of pharmacotherapy and cognitive-behavioural measures is recommended. New developments are aimed at achieving a more rapid and broader effect, together with improved tolerability, as far as possible also in multimorbid patients. Among the benzodiazepines, saliva.-soluble forms are being developed. New developments among the antidepressants, for example, include the pure S-enantiomer, escitalopram, slow-release paroxetine, and the serotonin and norepinephrine re-uptake inhibitor, duloxetine. New treatment strategies include augmentation with atypical antipsychotics. Furthermore, selective serotonin receptor ligands, new GABAA ligands, anticonvulsive drugs, neuropeptides, neurosteroids and modulators of the neuroendocrine stress reaction are all in the pipeline.

Literatur

  • 1 Amital D, Fostick L, Sasson Y, Kindler S, Amital H, Zohar J. Anxiogenic effects of Sumatriptan in panic disorder: a double-blind, placebo controlled study.  Eur Neropsychopharmacol. 2005;  15 279-283
    PubMedGoogle Scholar
  • 2 Atack JR. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.  Curr Drug Targets CNS Neurol Disord. 2003;  2 213-232
    CrossrefPubMedGoogle Scholar
  • 3 Bandelow B, Zohar J, Hollander E. et al. . WFSBP Task force on treatment guidelines for the pharmacological treatment of anxiety-obsessive compulsive disorders and posttraumatic stress disorder.  World J Biol Psychiatry. 2002;  3 171-199
    Google Scholar
  • 4 Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.  Am J Psychiatry. 1995;  152 1084-6
    PubMedGoogle Scholar
  • 5 Chao IL. Olanzapin augmentation in panic disorder: a case report.  Pharmacopsychiatry. 2004;  37 239-240
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Crane DL. Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders.  CNS Spectr. 2005;  10 176-179
    PubMedGoogle Scholar
  • 7 Deren-Wesolek A, Tatarczynska E, Chojnacka-Wojcik E. The novel buspirone analogue, 8-(4-(2-(1,2,3,4-tetrahydroisoquinolinyl)(butyl)-8-azaspiro (4.5) decane-7,9-dione, with aniolytic-like and antidepressant-like effects in rats.  J Psychopharmacol. 1998;  12 380-384
    PubMedGoogle Scholar
  • 8 Halbreich U. Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression.  Acta Psychiatr Scand. 1997;  95 169-176
    PubMedGoogle Scholar
  • 9 Healy DG, Harkin A, Cryan JF. et al. . Metyrapone displays antidepressant-like properties in preclinical paradigms.  Psychopharmacology. 1999;  145 303-308
    CrossrefPubMedGoogle Scholar
  • 10 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.  J Psychiatr Res. 1999;  33 181-214
    CrossrefPubMedGoogle Scholar
  • 11 Javitt DC. Glutamate as a therapeutic target in psychiatric disorders.  Mol Psychiatry. 2004;  9 984-997
    CrossrefPubMedGoogle Scholar
  • 12 Keck ME, Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders.  Peptides. 2001;  22 835-844
    CrossrefPubMedGoogle Scholar
  • 13 Keck ME, Welt T, Muller MB. et al. . The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stressinduced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats.  Pharmacopsychiatry. 2003;  36 27-31
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Klodzynska A, Tatarczynska E, Stachowicz K, Chojnacka-Wojcik E. The anxiolytic-like activity of AIDA (1-aminoindan-1,5-dicarboxolic acid), an mGlu 1 receptor antagonist.  J Physiol Pharmacol. 2004;  55 113-126
    PubMedGoogle Scholar
  • 15 Kramer MS, Cutler N, Feighner J. et al. . Distinct mechanism for antidepressant activity by blockade of central substance P receptors.  Science. 1998;  281 1640-1645
    CrossrefPubMedGoogle Scholar
  • 16 Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I. Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges.  Pharmacopsychiatry. 2005;  38 24-29
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Kuhl H. Sexualhormone und Psyche. Stuttgart, New York: Thieme 2002
    Google Scholar
  • 18 Lamberty Y, Falter U, Gower AJ, Klitgaard H. Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat.  Eur J Pharmacol. 2003;  469 97-102
    CrossrefPubMedGoogle Scholar
  • 19 JM Le Melledo, G Baker. Role of progesterone and other neuroactive steroids in anxiety disorders.  Expert Rev Neurother. 2004;  4 851-860
    CrossrefPubMedGoogle Scholar
  • 20 Liebsch F, Landgraf R, Engelmann M. et al. . Differential behavioural effects of chronic infusion of CRH1 and CRH2 receptor antisense oligonucleotides into the rat brain.  J Psychiatry Res. 1999;  33 153-163
    PubMedGoogle Scholar
  • 21 Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABA-A receptor. Mechanisms of action and physiological significance.  Prog Neurobiol. 1992;  38 379-395
    CrossrefPubMedGoogle Scholar
  • 22 Moroz G. High-potency benzodiazepines: recent clinical results.  J Clin Psychiatry. 2004;  65 13-18
    PubMedGoogle Scholar
  • 23 Murphy BE, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486.  J Psychiatry Neurosci. 1993;  18 209-213
    PubMedGoogle Scholar
  • 24 Nutt DJ, Forshall S, Bell C. et al. . Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders.  Eur Neuropsychopharmacol. 1999;  9 81-86
    CrossrefPubMedGoogle Scholar
  • 25 O'Dwyer AM, Lightman SL, Marks MN. et al. . Teatment of amjor depression with metyrapone and hydrocortisone.  J Affect Disord. 1995;  33 123-128
    CrossrefPubMedGoogle Scholar
  • 26 Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.  J Clin Psychopharmacol. 2001;  21 335-9
    CrossrefPubMedGoogle Scholar
  • 27 Pande AC, Pollack MH, Crockatt J. et al. . Placebo-controlled of gabapentin treatment of panic disorder.  J Clin Psychopharmacol. 2000;  20 467-471
    CrossrefPubMedGoogle Scholar
  • 28 Pecknold JC, Luthe L, Scott MH Fleury. et al. . Gepirone and the treatment of panic disorder: an open study.  J Clin Psychopharmacol. 1993;  13 145-149
    PubMedGoogle Scholar
  • 29 Pelletier G, Steinbusch HW, Verhofstad AA. Immunoreactive substance P and serotonin present in the same dense-core vesicles.  Nature. 1981;  293 71-72
    CrossrefPubMedGoogle Scholar
  • 30 Pigott TA. Gender differences in the epidemiology and treatment of anxiety disorders.  J Clin Psychiatry. 1999;  60 4-15
    PubMedGoogle Scholar
  • 31 Reddy DS. Pharmacology of endogenous neuroactive steroids.  Crit. Rev. Neurobiol. 2003;  15 197-234
    PubMedGoogle Scholar
  • 32 Rickels K. Alprazolam extended-release in panic disorder.  Expert Opin Pharmacother. 2004;  5 1599-1611
    CrossrefPubMedGoogle Scholar
  • 33 Roy-Byrne PP. The GABA-benzodiazepine receptor complex: structure, function and role in anxiety.  J Clin Psychiatry. 2005;  66 14-20
    PubMedGoogle Scholar
  • 34 Sandford JJ, Forshall S, Bell C. et al. . Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder.  J Psychopharmacol. 2001;  15 205-208
    PubMedGoogle Scholar
  • 35 Sargent PA, Kjaer KH, Bench CJ. et al. . Brain serotonin1A receptor binding measured by positron emission tomography with (11C)WAY-100635: effects of depression and antidepresan treatment.  Arch Gen Psychiatry. 2000;  57 174-180
    CrossrefPubMedGoogle Scholar
  • 36 Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.  Stress. 2003;  6 189-197
    PubMedGoogle Scholar
  • 37 Schweizer E. Generalized anxiety disorder. Longitudinal course and pharmacologic treatment.  Psychiatr Clin North Am. 1995;  18 843-857
    PubMedGoogle Scholar
  • 38 Serradeil-Le Gal C, Wagnon J 3rd, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A. An overview of SSR149415, a selective nonpeptide vasopressin V (1b) receptor antagonist.  CNS Drug Reviews. 2005;  11 53-68
    PubMedGoogle Scholar
  • 39 Sheehan DV, Burnham DB, Iyengar MK, Perera P, Paxil CR. Panic Disorder Study Group . Efficacy and tolerability of controlled release paroxetine in the treatment of panic disorder.  J Clin Psychiatry. 2005;  66 34-40
    CrossrefPubMedGoogle Scholar
  • 40 Ströhle A, Jahn H, Montkowski A. et al. . Central and peripheral administration of atriopeptin is anxiolytic in rats.  Neuroendocrinology. 1997;  65 210-215
    PubMedGoogle Scholar
  • 41 Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, Link N, Pollack MH. An open-label study of levetiracetam for the treatment of social anxiety disorder.  J Clin Psychiatry. 2004;  65 1219-1222
    PubMedGoogle Scholar
  • 42 Spooren W, Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics?.  Drug News Perspect. 2004;  17 251-257
    CrossrefPubMedGoogle Scholar
  • 43 Ströhle A, Kellner M, Holsboer F. et al. . Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.  Am J Psychiatry. 2001;  158 1514
    Google Scholar
  • 44 Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wojcik E. Effects of a selective 5-HT1b receptor agonist and antagonists in animal models of anxiety and depression.  Behav Pharmacol. 2004;  15 523-534
    PubMedGoogle Scholar
  • 45 Van Megen HJ, Westenberg HG, Den Boer JA. et al. . The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.  Psychopharmacology Berl. 11997;  29 243-248
    PubMedGoogle Scholar
  • 46 EC Van Geffen, JG Hugtenburg, ER Heerdink, RP van Hulten, AC Egberts. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005
    Google Scholar
  • 47 Van Vliet IM, Westenberg HG, Den Boer JA. Effects of the 5HT1A receptor agonist flesonoxan in panic disorder.  Psychopharmacology Berl. 1996;  127 174-180
    PubMedGoogle Scholar
  • 48 Vendruscolo LF, Takahashi RN, Bruske GR, Ramos A. Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ in anxiety-related behaviors.  Psychopharmacology. 2003;  170 287-293
    CrossrefPubMedGoogle Scholar
  • 49 Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.  J Clin Psychiatry. 2002;  63 31-7
    CrossrefPubMedGoogle Scholar
  • 50 Wedekind D, Bandelow B. Die Alpha-2-Delta Untereinheit des spannungsabhängigen Kalziumkanals. Ein neues pharmakologisches Ziel in der Psychiatrie und Neurologie. Nervenarzt
    Google Scholar
  • 51 Wolkowitz OM, Reus VI, Chan T. et al. . Antiglucocorticoid treatment of depression: double-blindketokonazole.  Biol Psychiatry. 1999;  45 1070-1074
    CrossrefPubMedGoogle Scholar
  • 52 Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.  Int Clin Psychopharmacol. 2005;  20 9-11
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse:

Dr. med. Dirk Wedekind
MScProf. Dr. med. Dipl.-Psych. Borwin Bandelow

Klinik für Psychiatrie und Psychotherapie der Georg-August-Universität Göttingen

Von-Siebold-Straße 5

37075 Göttingen

Email: dwedeki1@gwdg.de